Compare Merck & Co., Inc. (MRK) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Western Union Co — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while Western Union Co trades at $8.9 (market cap $2.71B). The key difference: Merck & Co., Inc. is far larger — about 113.4× Western Union Co's market cap, and Western Union Co pays the higher dividend (10.85%). Which is the better fit depends on your goals.
| MRK | WU | |
|---|---|---|
Market Cap | $307.25B | $2.71B |
Sector | Health | Technology |
52-Week High | $129.52 | $10.28 |
52-Week Low | $77.60 | $7.04 |
Enterprise Value | $350.66B | $2.40B |
Dividend Yield | 2.73% | 10.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Western Union (WU) trades at $8.46, down 4.73% on the day, with a bullish technical signal but mixed sentiment. The stock shows attractive valuation metrics with a P/E of 6.37 and P/S of 0.69, supported by strong profitability including a 10.88% net margin and 47.66% ROE. Recent developments include a partnership with Total Wireless and pending acquisition of Intermex, while Q1 2026 earnings missed expectations. Cash flow trends show volatility, with 2025 net cash flow negative $469.2 million.
Outlook remains cautious due to declining revenue trends and mixed analyst ratings, with 58% hold recommendations. The 11% dividend yield offers income appeal, but competitive pressures and execution risks on digital transformation pose challenges. Near-term catalyst is Q2 2026 results on July 30, 2026, with consensus EPS estimate of $0.43.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
